Seeking Alpha

LSYMD's  Instablog

Send Message
I am an MD by background who runs a healthcare hedge fund. I worked as a sell-side medical analyst for 20 years, covering pharmaceuticals, medical devices, PBMs and drug distributors.
  • GILD--Solvadi Prescription Data Continue Strong In Third Week 5 comments
    Jan 3, 2014 1:32 PM | about stocks: GILD

    Prescription data for Gilead's (NASDAQ:GILD) oral Hepatitis C drug, Solvadi, were released today, and reflect its third week on the market. As this was a holiday shortened week, with December 25 on a Wednesday, it was expected that thee would be a sequential drop. As reported by Symphony Health Solutions, Solvadi prescriptions fell by 5% sequentially. Importantly, prescriptions for the two protease inhibitors, Incivek and Victrelis, fell by 49% and 38%, respectively. Solvadi now commands an estimated 65% of the NS5B Inhibitor + Protease Inhibitor market in the US, versus 58% in the prior week. JNJ's Olysio represents 35% of the PI market, having surpassed Incivek, again reflecting the shift to the newer, more effective medications. Prescription data to be reported next week will reflect the holiday shortened January 1, 2014 period.

    I continue to forecast Gilead's sales of Hepatitis C pharmaceuticals to be $8 billion in 2014, versus consensus of $2.8 billion. I expect the number of patients treated in the US to exceed 125,000, given historical trends in the 80,000-120,000 range, the warehousing of patients in 2013 and the greater number of doctors, including infectious disease specialists, prescribing. On a worldwide basis, I believe Gilead's 2015 Hepatitis C revenues will exceed $15 billion, and that the company will earn $7 per share. Beyond 2015, I expect continued growth in Hepatitis C-related revenues as well as contributions from the company's late stage pipeline. This should result in a forward growth rate of 18%. With the stock currently selling at 10.6x my 2015 EPS estimate, I continue to look at the prospect of significant price appreciation, with limited downside risk.

    Disclosure: I am long GILD. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

    Themes: long-ideas Stocks: GILD
Back To LSYMD's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (5)
Track new comments
  • User 19588701
    , contributor
    Comments (6) | Send Message
    Also, I believe you misspelled Sovaldi.
    4 Jan, 01:44 AM Reply Like
  • User 19588701
    , contributor
    Comments (6) | Send Message
    Well written bit about Gilead.
    Where can you find prescription data for Sovaldi online?
    4 Jan, 01:53 AM Reply Like
    , contributor
    Comments (71) | Send Message
    Author’s reply » correct about my misspelling....As I run a healthcare fund, I get the weekly numbers from Bloomberg or the brokerage firms
    4 Jan, 10:43 PM Reply Like
  • manig
    , contributor
    Comments (7) | Send Message
    How will Abbvie+Enta drug approval/availability will affect Sovaldi sales?--esp. if A+E offered it at lower price ( because of 5-6 Tabs per day).
    5 Jan, 12:48 PM Reply Like
    , contributor
    Comments (71) | Send Message
    Author’s reply » The AbbVie regimen offers good efficacy, comparable to the GILD FDC which will be on the market first. Because ritonavir is part of AbbVie's combination, it will be contraindicated in a small percent of patients. I have followed this industry for "too long", and rarely has price been the determining factor for branded therapies. That having been said, in my modeling, I assume a $65000 average realized treatment price for GILD, so I feel that I am already taking this into account. I think it is more important that the GILD FDC will be on the market, prescribed to patients, before the AbbVie regimen. I also expect this to be the largest drug category ever, and so my forecast for GILD does not assume 100% market share. Len
    5 Jan, 10:21 PM Reply Like
Full index of posts »
Latest Followers


More »

Latest Comments

Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.